非FDG乏氧显像剂
本综述评估了硝基咪唑衍生物、铜基显像剂、镓基显像剂及其他创新化合物等新兴非FDG乏氧放射性示踪剂,重点阐述其作用机制、生物分布与临床应用,并讨论乏氧显像的优势与挑战及显像技术进展,旨在为改善癌症诊断、治疗计划与监测提供见解。
要点
- 乏氧在肿瘤生物学中起关键作用,影响癌症进展、治疗抵抗与患者预后。
- [18F]F-FDG PET是代谢评估标准,但难以准确描绘乏氧肿瘤区域。
- 本综述评估硝基咪唑衍生物、铜基与镓基显像剂等非FDG乏氧示踪剂的作用机制、生物分布与临床应用。
核心结论
- 本综述旨在综合现有研究,为利用非FDG乏氧示踪剂改善癌症诊断、治疗计划与监测提供见解,最终促进更个性化、更有效的癌症诊疗。
研究设计与样本
- 本综述评估硝基咪唑衍生物、铜基显像剂、镓基显像剂及其他创新化合物等新兴非FDG乏氧放射性示踪剂。
主要发现
- 综述重点阐述所评估示踪剂的作用机制、生物分布与临床应用。
- 综述讨论乏氧显像相关的优势与挑战,以及增强肿瘤乏氧评估的显像技术最新进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypoxia plays a critical role in tumor biology, influencing cancer progression, treatment resistance, and patient prognosis. While 18-Fluorine fluoredeoxyglucose ([18F]F-FDG) PET imaging has been the standard for metabolic assessment, its limitations in accurately depicting hypoxic tumor regions necessitate the exploration of non-FDG hypoxia tracers. This review aims to evaluate emerging non-FDG radiotracers, such as nitroimidazole derivatives, copper-based agents, gallium-based agents and other innovative compounds, highlighting their mechanisms of action, biodistribution, and clinical applications. We will discuss the advantages and challenges associated with hypoxia imaging, as well as recent advancements in imaging techniques that enhance the assessment of tumor hypoxia. By synthesizing current research, this review seeks to provide insights into the potential of non-FDG hypoxia tracers for improving cancer diagnosis, treatment planning, and monitoring, ultimately contributing to more personalized and effective cancer care.
引用
- Mokoala KMG, Sathekge MM. Non-FDG hypoxia tracers. Semin Nucl Med. 2024. PMID: 39510855. doi:10.1053/j.semnuclmed.2024.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。